RRAS2 and ovarian carcinoma: To confirm these in silico observations, we used CRISPR–Cas9 gene editing to knockout the RRAS2 locus from A2780 cells (R-RAS2Q72L positive), two ovarian cancer cell lines that express the wild-type version of R-RAS2 (COV362 and COV504) and the breast CAL-51 cancer cell line (which is R-RAS2Q72L positive).